Newsroom | 91909 results

维也纳--(BUSINESS WIRE)--(美国商业资讯)-- AOP Health持续推进其在骨髓增生性肿瘤（一类特殊罕见血液癌症）领域的临床研究项目。这家专注于罕见病治疗的公司在美国佛罗里达州奥兰多市举行的2025年美国血液学会（ASH）第67届年会上，公布了两项科学研究的成果。这些研究结果为治疗策略提供了新见解。 ROP-ET与BESREMi-PASS研究 其中一项名为ROP-ET的临床研究，评估了罗培干扰素α-2b在原发性血小板增多症（ET）患者中的应用。该病以体内血小板过度生成为特征。该项前瞻性、多中心、单臂III期临床试验，旨在探究罗培干扰素α-2b对于无法接受现有细胞减灭疗法1的ET患者的安全性及有效性。 另一项BESREMi-PASS研究，则观察了该药物在真性红细胞增多症（PV）患者日常临床实践中的表现。PV是一种罕见的骨髓造血干细胞癌变，会导致红细胞、白细胞和血小板慢性增多。 致力满足未竟的医疗需求 两项研究都为罗培干扰素α-2b如何帮助罹患这些慢性血液肿瘤的患者提供了新见解。 AOP Health首席执行官Martin Steinhart总结道：“AOP Heal...

VIENNA--(BUSINESS WIRE)--AOP Health continua a portare avanti il suo programma di ricerca clinica sulle neoplasie mieloproliferative, un particolare gruppo di rari tumori del sangue. L’azienda, specializzata nelle malattie rare, ha presentato i risultati di due indagini scientifiche in occasione della 67a edizione del congresso annuale della American Society of Hematology (ASH) 2025, che si è svolta a Orlando, Florida, USA. I risultati offrono nuovi dati approfonditi sulle strategie terapeutich...

VIENNE--(BUSINESS WIRE)--AOP Health poursuit son programme de recherche clinique sur les néoplasmes myéloprolifératifs, un groupe particulier de cancers du sang rares. Spécialisée dans les maladies rares, la société a présenté les résultats de deux études scientifiques lors du 67e Congrès annuel 2025 de l’American Society of Hematology (ASH) qui se tient actuellement à Orlando, en Floride (États-Unis). Ces résultats apportent de nouvelles perspectives en matière de stratégies thérapeutiques. RO...

VIENA--(BUSINESS WIRE)--A AOP Health continua avançando em seu programa de pesquisa clínica em neoplasias mieloproliferativas, um grupo especial de cânceres raros do sangue. A empresa, especializada em doenças raras, apresentou os resultados de duas investigações científicas no 67º Encontro Anual da Associação da Sociedade Americana de Hematologia (ASH) de 2025, realizado em Orlando, FL, EUA. Os resultados fornecem novas percepções sobre estratégias de tratamento. ROP-ET e BESREMI PASS Um dos e...

VIENA--(BUSINESS WIRE)--AOP Health sigue avanzando en su programa de investigación clínica en neoplasias mieloproliferativas, un grupo particular de cánceres sanguíneos poco frecuentes. La empresa, especializada en enfermedades raras, presentó los resultados de dos estudios científicos en la 67.a Reunión Anual 2025 de la Sociedad Estadounidense de Hematología (ASH, por sus siglas en inglés), realizada en Orlando, Florida, EE. UU. Estos hallazgos aportan nuevos conocimientos sobre las estrategia...

VIENNA--(BUSINESS WIRE)--AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA...

ROTTERDAM, Niederlande--(BUSINESS WIRE)--Prodalim, ein weltweit führender Anbieter von Lösungen für Säfte und Spezialzutaten, gab heute die Übernahme von René Laurent, einem führenden Hersteller von Getränkearomen, von International Flavours & Fragrances Inc. (IFF) bekannt. René Laurent wurde 1885 in der Region Grasse, der Hauptstadt der Aroma- und Duftstoffindustrie in Südfrankreich, gegründet und ist eine traditionsreiche, vertrauenswürdige Marke, die sich auf Aromen für Getränke und einz...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT). Results were shared from the combined analysis of four-year data from the la...